Fresenius Kabi intros generic Cytoxan

Fresenius Kabi is offering Cyclophosphamide for Injection, a generic of Cytoxan, used in treating several forms of cancer. 

“The introduction of Cyclophosphamide for Injection adds another critical treatment to our broad and leading oncology portfolio that offers lower-cost options for treating cancer,” said John Ducker, president and CEO of Fresenius Kabi USA.

Supplied as 500 mg, 1 g, and 2 g single-dose vials of lyophilized powder, the drug can be administered intravenously or orally. Fresenius Kabi offers all lyophilized presentations of cyclophosphamide currently on the market. Cyclophosphamide for Injection is available through distributors or directly from Fresenius Kabi.

[Read more: Fresenius Kabi intros generic Tepadina]

Cyclophosphamide for Injection is an alkylating drug indicated for the treatment of:

• Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of the ovary, retinoblastoma, breast carcinoma; and
• Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy-proven minimal change nephrotic syndrome patients who failed to respond adequately or are unable to tolerate adrenocorticosteroid therapy.